Herein, we attempt to dissect a new perspective on the expression of NG2/CSPG4 in solid organ cancers, such as HCC, pancreatic ductal adenocarcinoma (PDAC), and cancers of the lungs or kidneys, and its clinical significance as a novel immunotherapeutic target (Figure 1). This evidence concerns the gene CSPG4 and hepatocellular carcinoma.